Human papillomavirus type 16 E6 protein and Human papillomavirus type 16 E7 protein (HPV16 E6/E7)

The HPV16 E6 and E7 proteins are viral oncoproteins expressed early during infection with high-risk human papillomavirus type 16. They are transcribed from the viral genome as a polycistronic message and play a key role in malignant transformation. E7 primarily inactivates the retinoblastoma protein (pRb), inducing uncontrolled cell-cycle progression; E6 promotes degradation of p53, blocking apoptosis and further destabilizing the genome. Both proteins synergize to disrupt host cell regulation, promote cell proliferation, facilitate immune evasion, and establish a tumorigenic environment. Because these proteins are only expressed in infected and malignant cells and are essential for cancer cell survival, they are considered prime therapeutic and diagnostic targets, especially for vaccine development and targeted immunotherapy. Detection of E6/E7 mRNA or protein is an established biomarker for HPV-driven malignancies, and clinical efforts focus on eliciting immune responses against these viral antigens to achieve tumor clearance. No human host enzyme, receptor, or transporter corresponds to "HPV16 E6/E7 antigen presentation"; instead, antigen presentation is a process by which these viral proteins are displayed on MHC molecules for immune recognition.

Other names

HPV16 E6 oncoproteinHPV16 E7 oncoproteinHPV16 E6/E7Human papillomavirus (HPV) 16 E6 proteinHuman papillomavirus (HPV) 16 E7 proteinE6/E7

Immunotherapeutic targeting: Induction of cytotoxic T-cell response against cells expressing E6/E7 antigens. Protein stability modulation: Chaperone inhibition leading to decreased E6/E7 levels and restoration of tumor suppressors (e.g., p53 and pRb). Transcriptional interference: Inhibition of E6/E7 transcription or translation has been explored in experimental models.